- Home
- »
- Biotechnology
- »
-
Bioprocess Validation Market Size & Share Report, 2033GVR Report cover
Bioprocess Validation Market (2026 - 2033)
Size, Share & Trends Analysis Report By Testing Type (Extractables & Leachables Testing, Bioprocess Residuals Testing), By Stage (Process Design, Process Qualification), By Mode, By Region, And Segment Forecasts
Market Size, 2025
$528.0MMarket Estimate, 2026
$574.5MMarket Forecast, 2033
$1,052.5MCAGR, 2026–2033
9.0%Bioprocess Validation Market Summary
The global bioprocess validation market size was valued at USD 528.0 million in 2025 and is projected to grow from USD 574.5 million in 2026 to USD 1,052.5 million by 2033, at a CAGR of 9.0% from 2026 to 2033. North America dominated the bioprocess validation market with the largest revenue share of 40.7% in 2025. Growth is driven by the rising demand for biologics and biosimilars, stringent regulatory requirements for product safety and efficacy, and the increasing adoption of single-use systems in manufacturing.
Source: Grand View Research, IR Documents, Primary Interviews, Paid DatabasesTo learn more about this report,
Download Free Sample Report Key Market Trends & Insights
- By testing type: Bioprocess residuals testing segment held the largest market share of 29.1% in 2025.
- By stage: Continued process verification segment held the largest market share of 42.4% in 2025.
- By mode: In house segment held the largest market share of 81.4% in 2025.
Regional Highlights
- Largest regional market: North America (40.7% revenue share, 2025)
- Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)
- By country: The U.S. held the largest market share in 2025
Market Size & Forecast
- Market size in 2025: USD 528.0 Million
- Estimated market size in 2026: USD 574.5 Million
- Projected market size by 2033: USD 1,052.5 Million
- CAGR (2026-2033): 9.0%
Prism AI by Grand View Research Free to tryAsk a question about the bioprocess validation marketTry asking✓Every figure cited from GVR research Prefer the report? Download free sample →
To learn more about this report, Download Free Sample Report Moreover, biopharmaceutical companies' shift toward outsourcing validation services to reduce costs and accelerate time-to-market is expected to support market expansion.
Market Dynamics
The bioprocess validation market is witnessing steady growth, supported by increasingly stringent regulatory requirements for manufacturing quality, process consistency, and product safety across the biopharmaceutical industry. Growing adoption of advanced manufacturing technologies, including continuous bioprocessing, and single-use systems is increasing the need for comprehensive validation throughout the product lifecycle. Moreover, rising investments in biopharmaceutical manufacturing infrastructure, expanding outsourcing of validation services to specialized CROs and CDMOs, and increasing implementation of digital validation and automation solutions are expected to support market growth over the forecast period.
The rising production of biologics and biosimilars strongly drives the demand for bioprocess validation. Biologics such as monoclonal antibodies, recombinant proteins, vaccines, and advanced therapies like cell and gene therapies are highly complex and sensitive to manufacturing variations. To ensure product safety, efficacy, and consistency, rigorous validation of every production stage, upstream, downstream, and final fill/finish is critical. Moreover, with the rapid growth of the biosimilars market following the expiration of major biologic patents, manufacturers are under increasing pressure to validate their processes to demonstrate comparability with reference products in line with strict regulatory requirements. This growing biologic pipeline and the global push for more cost-effective therapeutic solutions have made validation an indispensable step in biomanufacturing.
Biosimilars Approved by FDA (2025–2026)
Approval Date
Biosimilar (Nonproprietary Name)
15-May-26
Immgolis (golimumab-sldi) and Immgolis Intri (golimumab-sldi)
7-May-26
Ennumo (pegfilgrastim-pccg)
29-Apr-26
Langlara (insulin glargine-aldy)
27-Mar-26
Ponlimsi (denosumab-adet)
15-Jan-26
Filkri (filgrastim-laha)
15-Jul-25
Kirsty (insulin aspart-xjhz)
22-May-25
Starjemza (ustekinumab-hmny)
9-Apr-25
Jobevne (bevacizumab-nwgd)
25-Mar-25
Conexxence, Bomyntra (denosumab-bnht)
7-Mar-25
Omlyclo (omalizumab-igec)
28-Feb-25
Stoboclo, Osenvelt (denosumab-bmwo)
14-Feb-25
Merilog (insulin aspart-szjj)
13-Feb-25
Ospomyv, Xbryk (denosumab-dssb)
24-Jan-25
Avtozma (tocilizumab-anoh)
Source: Drugs.com, Secondary Research, Grand View Research[
Beyond product innovation, regulatory compliance, and evolving manufacturing technologies further accelerate market growth. Stringent guidelines issued by agencies such as the FDA, EMA, and PMDA require thorough validation of processes, analytical methods, and equipment to safeguard patient safety. The shift toward single-use bioprocessing systems has also intensified demand for extractables and leachable testing to ensure product purity. Moreover, outsourcing validation activities to contract research and manufacturing organizations allows companies to reduce costs, speed up production timelines, and access specialized expertise.
Beyond product innovation, regulatory compliance, and evolving manufacturing technologies further accelerate market growth. Stringent guidelines issued by agencies such as the FDA, EMA, and PMDA require thorough validation of processes, analytical methods, and equipment to safeguard patient safety. The shift toward single-use bioprocessing systems has also intensified demand for extractables and leachable testing to ensure product purity. Moreover, outsourcing validation activities to contract research and manufacturing organizations allows companies to reduce costs, speed up production timelines, and access specialized expertise.
Stringent regulatory requirements
One of the most significant factors driving the bioprocess validation market is the growing emphasis on stringent regulatory frameworks established by global health authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). These agencies mandate comprehensive validation of bioprocesses to ensure that biologics, biosimilars, and vaccines consistently meet the highest safety, efficacy, and quality standards. Regulatory guidelines require manufacturers to thoroughly validate every critical aspect of production, including equipment, sterilization methods, cleaning procedures, analytical assays, and overall process controls. Non-compliance can result in severe consequences such as product recalls, approval delays, hefty fines, and reputational damage, making compliance a top priority for pharmaceutical and biotechnology companies.
With the global expansion of biologics manufacturing, particularly in emerging markets, regulatory bodies are strengthening their oversight and harmonizing standards across regions. This has heightened the demand for advanced validation services and technologies to ensure adherence to Good Manufacturing Practices (GMP) and International Council for Harmonisation (ICH) guidelines. Moreover, the rising focus on patient safety and increasing scrutiny over manufacturing quality have prompted companies to adopt more rigorous and automated validation approaches. As a result, enforcing strict regulatory requirements compels companies to invest in robust validation strategies and serves as a long-term growth driver for the bioprocess validation market.
The continuously evolving regulatory landscape poses a significant challenge to the bioprocess validation market. Regulatory agencies such as the FDA, EMA, and other regional authorities frequently update guidelines related to process validation, data integrity, risk management, and quality assurance. Manufacturers operating across multiple regions must comply with varying regulatory expectations, increasing the complexity of validation planning and execution.
In addition, adapting validation protocols to meet new regulatory standards often requires additional testing, documentation, and process modifications, leading to higher operational costs and extended approval timelines. These challenges are particularly significant for small and mid-sized biopharmaceutical companies with limited regulatory expertise and resources, potentially delaying product development and commercialization.
Market Concentration & Characteristics
The bioprocess validation industry is witnessing high innovation, driven by the adoption of advanced analytical technologies, automation, and digital solutions. Traditional validation methods are rapidly being replaced with data-driven approaches such as real-time monitoring, process analytical technology (PAT), and risk-based validation strategies that improve accuracy and reduce time-to-market. Integrating artificial intelligence, machine learning, and cloud-based platforms enables predictive analytics and automated documentation, enhancing regulatory compliance and efficiency. For instance, in November 2024, MilliporeSigma in the United States highlighted an integrated approach to CPV and APQR, emphasizing digitalization to reduce redundancies, automate data collection, and enhance regulatory compliance efficiency. These advancements optimize operational workflows and allow biopharmaceutical companies to scale production with greater flexibility, making innovation a defining factor in the growth and competitiveness of the bioprocess validation market.
M&A activity in the bioprocess validation industry has been moderate to high, driven by the need for portfolio expansion, advanced validation technologies, and broader geographic reach. Key players such as Thermo Fisher Scientific, Merck KGaA, Sartorius, and Danaher have pursued strategic acquisitions of validation service providers and technology innovators to strengthen end-to-end offerings. For instance, in October 2024, Lonza’s USD 1.2 billion Vacaville acquisition expanded US biologics capacity, driving a greater need for bioprocess validation to ensure compliance, consistency, and efficiency in large-scale mammalian manufacturing. These targeted deals and regional collaborations enable companies to meet rising demand for biologics manufacturing and regulatory compliance, a trend likely to continue in the coming years.
To learn more about this report, Download Free Sample Report Regulations play a decisive role in shaping the industry, as agencies such as the FDA, EMA, and PMDA enforce strict guidelines to ensure product safety, efficacy, and quality. Compliance with Good Manufacturing Practices (GMP) and International Council for Harmonisation (ICH) requires extensive validation of processes, equipment, and analytical methods, making regulatory oversight a key market driver. While these stringent requirements increase operational costs and complexity, they also create steady demand for specialized validation services and technologies. As global regulators harmonize standards and intensify scrutiny, companies are investing more in automated, data-driven validation approaches to achieve compliance efficiently, thereby reinforcing the critical influence of regulations on market growth.
Product expansion is a key strategy in the market, with companies introducing new kits, analytical platforms, and single-use testing solutions to meet evolving needs. Innovations in extractables and leachable testing, viral clearance validation, and digital tools such as automation and real-time monitoring enable firms to enhance compliance and efficiency while strengthening their competitive edge.
Regional expansion is emerging as a core growth strategy in the industry, as leading players strengthen their presence in high-growth regions such as Asia-Pacific and Latin America. Rising biologics manufacturing, supportive government initiatives, and expanding clinical research activities in China, India, and Brazil drive demand for localized validation services and facilities. Global companies invest in new laboratories, partnerships, and technology transfers to capture these opportunities, ensuring compliance with regional regulatory standards while broadening their customer base.
Analyst Perspective
The bioprocess validation market is expected to witness steady growth, driven by the expanding biopharmaceutical industry, increasing production of biologics and biosimilars, and stringent regulatory requirements for product quality and process consistency. Rising adoption of advanced manufacturing technologies and quality-by-design (QbD) approaches is increasing the demand for robust validation solutions across upstream and downstream bioprocesses. Growing investments in cell & gene therapies and continuous bioprocessing, coupled with the need to ensure regulatory compliance and operational efficiency, are expected to support long-term market growth. Market participants are focusing on automation, digital validation tools, and integrated quality management solutions to strengthen their competitive position.
Testing Type Insights
Based on testing type, the bioprocess residuals testing segment held the largest revenue share of over 29.1% in 2025. Residual testing includes impurities such as cell culture-derived upstream and downstream impurities, buffer contents, and anti-foam agents. There is a huge demand for impurity-free, safe, quality drug, vaccine, and therapeutic products manufactured by the biotechnology, biopharmaceutical, and pharmaceutical industries.
The extractables and leachables segment is the fastest-growing bioprocess validation industry, driven by cGMP guidelines and strict FDA regulations that demand certified, high-quality bioproducts. Biopharma companies increasingly focus on identifying hazards from leachables in processing systems and packaging to ensure product safety and integrity, fueling strong market growth.
Stage Insights
Based on stage, the continued process verification segment held the largest revenue share of over 42.4% in 2025. This segment involves systematically collecting, storing, processing, and analyzing data from every production batch to ensure consistent quality and compliance with regulatory standards. The increasing adoption of automation and digital tools in process verification further enhances efficiency, accuracy, and real-time monitoring, thereby driving the growth of this segment.
The process design segment is projected to grow fastest during the forecast period, representing the most critical step in bioprocess validation. Effective process design establishes stringent manufacturing protocols, pathways, and concepts, ensuring efficiency, reproducibility, and compliance with regulatory standards. Strong process design is a key driver behind the segment’s rapid growth by enabling consistent production of high-quality bioproducts.
Mode Insights
Based on mode, the in house segment held the largest revenue share of over 81.4% in 2025. Many biopharmaceutical companies and industries prefer to manufacture raw materials and tools required for the bioprocess validation process internally to maintain control over quality and production. Moreover, increasing funding, mergers, and collaborations to develop advanced bioprocess validation bioprocess validation further support this segment's growth.
To learn more about this report, Download Free Sample Report The outsourced segment is expected to grow at the fastest CAGR during the forecast period. The rising demand for testing services among biopharmaceutical and biotechnology companies engaged in bioproduct manufacturing and validation is a key driver of this growth. Outsourcing has become a preferred strategy in biopharma drug and therapeutics production, as it ensures scalability, quality, and regulatory compliance. For instance, in July 2025, BioPlan Associates (U.S.) reported record levels of outsourcing across bioprocess platforms, highlighting the role of CDMOs as strategic partners in global biomanufacturing. Moreover, increasing healthcare expenditure and the steady supply of raw materials from market players further contribute to the expansion of this segment.
Regional Insights
North America dominated the bioprocess validation market with the largest revenue share of 40.7% in 2025. The region’s leadership is attributed to the strong presence of outsourcing services, the rapid growth of life science research, and the rising production of biologics. The concentration of key market players such as Thermo Fisher Scientific Inc., Danaher Corporation, and Eurofins further strengthens the region’s position. For instance, in June 2022, the Jefferson Institute for Bioprocessing expanded US biologics training to Budd Bioworks, offering workforce development in bioprocessing, analytical testing, and cell and gene therapies.
To learn more about this report, Download Free Sample Report U.S Bioprocess Validation Market Trends
The bioprocess validation market in the U.S. held the largest share in the North America region in 2025. The bioprocess validation market in the U.S. is growing due to the strong presence of FDA-approved biopharma manufacturers, CDMOs, and stringent regulatory standards. Rising investments in biologics and advanced therapies and increasing adoption of automation and digital validation tools are further driving demand.
Europe Bioprocess Validation Market Trends
The bioprocess validation market in Europe is driven by a strong biopharmaceutical base, supportive EMA regulations, and rising biosimilars production. Growing investments in advanced biomanufacturing facilities and collaborative R&D initiatives across Germany, the U.K., and France are boosting demand for validation services. In addition, increasing adoption of single-use technologies, strict quality compliance requirements, and leading players such as Sartorius, Merck KGaA, and Lonza further strengthen the region’s position as a key hub for bioprocess validation.
The UK bioprocess validation market is growing due to strong government support for life sciences, rising investments in biosimilars and advanced therapies, and the adoption of single-use technologies. Collaboration across academia and industry and strict EMA and MHRA compliance further drive demand for validation services.
The bioprocess validation market in Germany leads the European market with its strong biopharmaceutical manufacturing base, advanced R&D infrastructure, and strict regulatory compliance. Rising biosimilars production, biomanufacturing facility expansion, and major players like Sartorius and Merck KGaA are key drivers of validation demand. Moreover, government support for life science innovation, increased clinical trial activity, and the rapid adoption of automation and single-use systems further strengthen Germany’s position as a hub for bioprocess validation in Europe.
Asia Pacific Bioprocess Validation Market Trends
The bioprocess validation market in Asia-Pacific is expected to witness the fastest CAGR of 9.5% during the forecast period. This growth is driven by rising investments in biopharmaceutical manufacturing, expanding clinical research, supportive government initiatives, and increasing adoption of single-use technologies across countries such as China, India, South Korea, and Japan. The presence of a large patient pool, growing biosimilars demand, and the entry of global players through partnerships and facility expansions further position Asia-Pacific as a high-potential market.
China bioprocess validation market is expanding rapidly, supported by strong government investment in biopharmaceutical manufacturing, growing demand for biosimilars, and a rising focus on cell and gene therapies. The country’s regulatory framework increasingly aligns with global standards, driving higher compliance and validation needs. Moreover, partnerships with global CDMOs, expansion of local manufacturing facilities, and adoption of single-use systems further fuel market growth.
The bioprocess validation industry in Japan is driven by its strong pharmaceutical industry, advanced R&D ecosystem, and strict regulatory oversight by the PMDA. Growing investments in regenerative medicine, cell and gene therapies, and biosimilars production are boosting validation demand. Moreover, collaborations between global players and domestic firms, along with the adoption of automation and continuous bioprocessing technologies, further strengthen Japan’s position as a key market in Asia-Pacific.
Middle East & Africa Bioprocess Validation Market Trends
The bioprocess validation market in the Middle East and Africa is witnessing steady growth, supported by increasing investments in healthcare infrastructure, expanding clinical research, and the rising demand for biologics. Countries such as the UAE, Saudi Arabia, and South Africa focus on developing biomanufacturing capabilities, while collaborations with global players and adopting international regulatory standards drive demand for validation services across the region.
Kuwait bioprocess validation market is growing with rising healthcare investments, government support for biotechnology, and increasing demand for biologics. Collaborations with global players and alignment with international standards further drive validation service adoption.
Key Bioprocess Validation Companies Insights
Key players operating in the bioprocess validation market are undertaking various initiatives to strengthen their presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are key in propelling the market growth.
To learn more about this report, Download Free Sample Report Key Bioprocess Validation Companies
The following key companies have been profiled for this study on the bioprocess validation market.
-
Eurofins Scientific, Inc.
-
Sartorius AG
-
Merck KGaA
-
Thermo Fisher Scientific Inc.
-
Lonza
-
Danaher Corporation
-
Charles River Laboratories
-
SGS S.A.
-
Toxikon Corporation
-
Cobetter Filtration Equipment Co., Ltd.
Competitive Benchmarking
Category
Operating Strategies
Competitive Edge
Weakness
Established Players (Thermo Fisher Scientific, Merck KGaA, Sartorius AG, Danaher Corporation, etc.)
- Strengthen global presence through strategic partnerships, laboratory expansion, and investments in biologics, biosimilars, and cell & gene therapy validation capabilities.
- Comprehensive validation expertise supported by broad analytical technologies, global laboratory networks, and strong regulatory compliance capabilities.
- Significant operational costs associated with maintaining advanced testing infrastructure and evolving global compliance standards.
Emerging Players (Toxikon Corporation, Cobetter Filtration Equipment Co., Ltd., SGS S.A.)
- Expand market presence through application-specific product development and partnerships with regional biopharmaceutical manufacturers.
- Ability to address specialized bioprocess validation requirements with cost-effective and application-focused offerings.
- Narrower product and service portfolios, limiting participation across the complete bioprocess validation workflow.
Recent Development
- In April 2026, Saint-Gobain Bioprocess Solutions and VERDOT entered into a strategic collaboration to develop and commercialize an integrated pre-use post-sterilization integrity testing (PUPSIT) solution, strengthening bioprocess validation capabilities by supporting GMP-compliant sterile filtration validation and regulatory compliance under EU GMP Annex 1.
Bioprocess Validation Market Report Scope
Report Attribute
Details
Market size in 2025
USD 528.0 million
Estimated market size in 2026
USD 574.5 million
Projected market 2033
USD 1,052.5 million
Growth rate
CAGR of 9.0% from 2026 to 2033
Historical data
2021 - 2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million, and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Testing type, stage, mode, and region
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, Norway, Denmark, Sweden, China, Japan, India, South Korea, Australia, Thailand, Brazil, Argentina, Saudi Arabia, South Africa, UAE, and Kuwait
Key companies profiled
Eurofins Scientific, Inc.; Sartorius AG; Merck KGaA; Thermo Fisher Scientific Inc.; Lonza; Danaher Corporation; Charles River Laboratories; SGS S.A.; Toxikon Corporation; Cobetter Filtration Equipment Co., Ltd.
Customization scope
Free report customization (equivalent up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global Bioprocess Validation Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global bioprocess validation market report on the basis of testing type, stage, mode, and region
To learn more about this report, Download Free Sample Report -
Testing Type Outlook (Revenue, USD Million, 2021 - 2033)
-
Extractables & Leachables Testing
-
Bioprocess Residuals Testing
-
Viral Clearance Testing
-
Filtration & Fermentation Systems Testing
-
Others
-
-
Stage Outlook (Revenue, USD Million, 2021 - 2033)
-
Process Design
-
Process Qualification
-
Continued Process Verification
-
-
Mode Outlook (Revenue, USD Million, 2021 - 2033)
-
In house
-
Outsourced
-
-
Regional Outlook (Revenue, USD Million, 2021 - 2033)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
China
-
Japan
-
India
-
Australia
-
Thailand
-
South Korea
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Research Methodology
The bioprocess validation market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each bioprocess validation segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment- Testing Type
Revenue Capture Definition
Extractables & Leachables Testing
Revenue generated from validation services and analytical testing performed to identify, characterize, and quantify chemical compounds that may migrate from manufacturing equipment, single-use systems, packaging materials, and process components into biopharmaceutical products. These studies support product safety, regulatory compliance, and process qualification throughout biomanufacturing operations.
Bioprocess Residuals Testing
This segment captures income from testing services used to detect and quantify residual impurities remaining after bioprocessing, including host cell proteins, host cell DNA, residual Protein A, process chemicals, media components, antibiotics, and other manufacturing-related contaminants. Such testing ensures product purity, quality, and compliance with regulatory specifications.
Viral Clearance Testing
Market value in this category stems from validation studies designed to demonstrate the ability of manufacturing processes to remove or inactivate viral contaminants. These services support regulatory submissions and ensure the viral safety of biologics, monoclonal antibodies, recombinant proteins, vaccines, and other biopharmaceutical products.
Filtration & Fermentation Systems Testing
Revenue originates from validation services assessing the performance, integrity, efficiency, and consistency of filtration and fermentation systems used during biopharmaceutical manufacturing. These studies verify system reliability, contamination control, process robustness, and compliance with current good manufacturing practices (cGMP).
Others
This segment reflects earnings from specialized bioprocess validation testing services not included within the primary categories, including cleaning validation, container closure integrity testing, equipment qualification support, and other customized analytical validation services required during biopharmaceutical manufacturing.
Segment- Stage
Revenue Capture Definition
Process Design
Revenue generated from validation activities performed during the initial development of manufacturing processes to establish process understanding, define critical process parameters, optimize operating conditions, and ensure consistent product quality before commercial production.
Process Qualification
This segment captures income from validation studies conducted to confirm that manufacturing facilities, equipment, utilities, and production processes consistently operate within predefined acceptance criteria and are capable of producing products meeting established quality standards.
Continued Process Verification
Market value in this category stems from ongoing monitoring and validation activities performed throughout commercial manufacturing to verify sustained process performance, identify variability, maintain regulatory compliance, and ensure consistent product quality over the product lifecycle.
Segment- Mode
Revenue Capture Definition
In House
Revenue generated from bioprocess validation activities conducted internally by biopharmaceutical manufacturers using their own analytical laboratories, quality assurance teams, validation specialists, and manufacturing infrastructure. This approach provides greater operational control, data ownership, and integration with internal quality management systems.
Outsourced
This segment captures income from bioprocess validation services provided by contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), specialized testing laboratories, and third-party validation providers. Outsourcing enables access to advanced analytical capabilities, regulatory expertise, and flexible validation resources while reducing internal infrastructure requirements.
Estimation Model
To learn more about this report, Download Free Sample Report Delivered Customizations
This report has been delivered with the following In-depth customizations
Client Request
Customization Delivered
Value Adds
Bioprocess Validation Workflow & Testing Type Analysis
Comprehensive cross-segmentation across validation workflow stages (Process Design, Process Qualification, Continued Process Verification) and testing types including extractables & leachables, bioprocess residuals, viral clearance, and filtration & fermentation systems. Analysis includes adoption by biologics, biosimilars, vaccines, cell & gene therapies, and CDMO manufacturing environments.
Enables clients to identify high-growth validation service opportunities, prioritize investments across testing technologies, evaluate validation requirements by bioprocess stage, and optimize service portfolios for emerging biopharmaceutical modalities.
Competitive Benchmarking & Outsourcing Landscape Assessment
Detailed benchmarking of validation service providers based on testing capabilities, regulatory compliance expertise (FDA, EMA, ICH), geographic presence, laboratory infrastructure, bioprocess validation portfolio, partnerships with biopharma/CDMOs, pricing strategy, and recent capacity expansions. Includes comparative analysis of in-house versus outsourced validation models.
Helps clients benchmark competitive positioning, identify strategic outsourcing opportunities, evaluate partnership and acquisition targets, and develop differentiated market entry and expansion strategies within the bioprocess validation ecosystem.
Application & End-use Opportunity Assessment
Customized analysis of bioprocess validation demand across applications including monoclonal antibodies, vaccines, recombinant proteins, cell & gene therapies, and biosimilars. Further segmented by end users such as biopharmaceutical companies, CDMOs/CMOs, and research organizations, with assessment of validation requirements, outsourcing trends, and technology adoption patterns.
Enables clients to identify high-growth application areas and end-user segments, evaluate evolving validation requirements, prioritize commercial opportunities, and tailor product and service strategies to specific biopharmaceutical manufacturing needs.
Frequently Asked Questions About This Report
Some key players operating in the bioprocess validation market include Eurofins Scientific, Inc.; Sartorius AG; Merck KGaA; Thermo Fisher Scientific, Inc.; Lonza; Danaher Corporation; Charles River Laboratories; SGS S.A.; Toxikon Corporation; and Cobetter Filtration Equipment Co., Ltd.
Key factors driving the bioprocess validation market include the increasing stringency in the U.S. FDA guidelines and cGMP regulation for biopharmaceutical production as well as the rising demand for high-quality biopharmaceuticals for the treatment of chronic and infectious diseases
The global bioprocess validation market size was estimated at USD 528.0 million in 2025 and is expected to reach USD 574.5 million in 2026.
The bioprocess residuals testing segment held the largest revenue share of over 29.1% in 2025.
The continued process verification segment held the largest revenue share of over 42.4% in 2025.
The in-house segment held the largest revenue share of over 81.4% in 2025.
Asia Pacific is the fastest-growing region over the forecast period.
The global bioprocess validation market is expected to grow at a compound annual growth rate of 9.0% from 2026 to 2033 to reach USD 1,052.5 million by 2033.
North America dominated the bioprocess validation market with a share of 40.7% in 2025. This is attributable to an established healthcare sector and rising demand for biopharmaceuticals in the region.
About the Author(s)
Biotechnology Research Team
Healthcare · BiotechnologyThis report was authored by the biotechnology research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the biotechnology segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
